Presenters
Professor of Clinician Scientist and Program
Prof. Merlin Thomas
Course Details
Prof. Merlin Thomas discusses practical measures in the use of SGLT2i for patients with T2D. This includes handling of complaints of increased urination and even genital mycotic infections for patients taking SGLT2i. The video also discusses monitoring of HbA1c and kidney function after initiation of treatment.
Estimated time of Completion: 18 Mins 47 Secs
CPD Points: 1 CPD point
SGLT2i Practical Points Course Outline
Section 1
- What can my patient with T2D expect when starting an SGLT2 inhibitor?
- Complaints if increased urination with SGLT2i
- Increased Risk of genital mycotic infection
- Genital infections, but not UTIs, with SGLT2 inhibitors are common, typically mild to moderate in severity and easily managed
- EMPA-REG OUTCOME – no increase in urinary tract infection, no more UTIs in those with history of UTIs
Section 2
- How can I help them to reduce the risk of serious problems when starting an SGLT2i?
Section 3
- Time to reduce glucose levels
- The response depends on the baseline HbA1C and eGFR
- Early combination therapy can be appropriate
- Do you need to monitor kidney function?